Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab

被引：1
作者：
Chikaishi, Yasuhiro [1 ,2 ]
Tanaka, Fumihiro [2 ]
Honda, Yohei [1 ]
Inoue, Masaaki [1 ]
Yoshida, Junichi [1 ]
Tanaka, Masao [1 ]
机构：
[1] Shimonoseki City Hosp, Dept Chest Surg, 1-13-1 Kouyouchou, Shimonoseki, Yamaguchi 7508520, Japan
[2] Univ Occupat & Environm Hlth, Sch Med, Dept Surg 2, Yahatanishi Ku, Kitakyushu, Fukuoka, Japan
来源：
TRANSLATIONAL CANCER RESEARCH | 2020年 / 9卷 / 03期
关键词：
CELL LUNG-CANCER; EGFR MUTATIONS; OPEN-LABEL; CHEMOTHERAPY; ADENOCARCINOMA; OSIMERTINIB; MULTICENTER; GEFITINIB; ERLOTINIB; SURVIVAL;
D O I：
10.21037/tcr.2020.01.24
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1307 / 1310
页数：4
相关论文
共 24 条
  • [1] Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L)
    Akamatsu, Hiroaki
    Teraoka, Shunsuke
    Morita, Satoshi
    Katakami, Nobuyuki
    Tachihara, Motoko
    Daga, Haruko
    Yamamoto, Nobuyuki
    Nakagawa, Kazuhiko
    [J]. CLINICAL LUNG CANCER, 2019, 20 (04) : E492 - E494
  • [2] [Anonymous], 2018, J CLIN ONCOL
  • [3] Effect of erlotinib plus bevacizumab on brain metastases in patients with non-small cell lung cancer
    Chikaishi, Yasuhiro
    Kanayama, Masatoshi
    Taira, Akihiro
    Nabe, Yusuke
    Shinohara, Shinji
    Kuwata, Taiji
    Takenaka, Masaru
    Oka, Soichi
    Hirai, Ayako
    Kuroda, Koji
    Imanishi, Naoko
    Ichiki, Yoshinobu
    Tanaka, Fumihiro
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (20)
  • [4] AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer
    Cross, Darren A. E.
    Ashton, Susan E.
    Ghiorghiu, Serban
    Eberlein, Cath
    Nebhan, Caroline A.
    Spitzler, Paula J.
    Orme, Jonathon P.
    Finlay, M. Raymond V.
    Ward, Richard A.
    Mellor, Martine J.
    Hughes, Gareth
    Rahi, Amar
    Jacobs, Vivien N.
    Brewer, Monica Red
    Ichihara, Eiki
    Sun, Jing
    Jin, Hailing
    Ballard, Peter
    Al-Kadhimi, Katherine
    Rowlinson, Rachel
    Klinowska, Teresa
    Richmond, Graham H. P.
    Cantarini, Mireille
    Kim, Dong-Wan
    Ranson, Malcolm R.
    Pao, William
    [J]. CANCER DISCOVERY, 2014, 4 (09) : 1046 - 1061
  • [5] EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
    Gainor, Justin F.
    Shaw, Alice T.
    Sequist, Lecia V.
    Fu, Xiujun
    Azzoli, Christopher G.
    Piotrowska, Zofia
    Huynh, Tiffany G.
    Zhao, Ling
    Fulton, Linnea
    Schultz, Katherine R.
    Howe, Emily
    Farago, Anna F.
    Sullivan, Ryan J.
    Stone, James R.
    Digumarthy, Subba
    Moran, Teresa
    Hata, Aaron N.
    Yagi, Yukako
    Yeap, Beow Y.
    Engelman, Jeffrey A.
    Mino-Kenudson, Mari
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (18) : 4585 - 4593
  • [6] Future Scenarios for the Treatment of Advanced Non-Small Cell Lung Cancer: Focus on Taxane-Containing Regimens
    Grossi, Francesco
    Kubota, Kaoru
    Cappuzzo, Federico
    de Marinis, Filippo
    Gridelli, Cesare
    Aita, Marianna
    Douillard, Jean-Yves
    [J]. ONCOLOGIST, 2010, 15 (10) : 1102 - 1112
  • [7] Afatinib Plus Bevacizumab Combination After Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Multicenter, Single-Arm, Phase 2 Trial (ABC Study)
    Hata, Akito
    Katakami, Nobuyuki
    Kaji, Reiko
    Yokoyama, Toshihide
    Kaneda, Toshihiko
    Tamiya, Motohiro
    Inoue, Takako
    Kimura, Hiromi
    Yano, Yukihiro
    Tamura, Daisuke
    Morita, Satoshi
    Negoro, Shunichi
    [J]. CANCER, 2018, 124 (19) : 3830 - 3838
  • [8] Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study)
    Hiranuma, Osamu
    Uchino, Junji
    Yamada, Tadaaki
    Chihara, Yusuke
    Tamiya, Nobuyo
    Kaneko, Yoshiko
    Yoshimura, Kenichi
    Takayama, Koichi
    [J]. CLINICAL LUNG CANCER, 2019, 20 (03) : E402 - E406
  • [9] Gefitinib Plus Bevacizumab vs. Gefitinib Alone for EGFR Mutant Non-squamous Non-small Cell Lung Cancer
    Kitagawa, Chiyoe
    Mori, Masahide
    Ichiki, Masao
    Sukoh, Noriaki
    Kada, Akiko
    Saito, Akiko M.
    Ichinose, Yukito
    [J]. IN VIVO, 2019, 33 (02): : 477 - 482
  • [10] Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis
    Lee, Chee Khoon
    Wu, Yi-Long
    Ding, Pei Ni
    Lord, Sarah J.
    Inoue, Akira
    Zhou, Caicun
    Mitsudomi, Tetsuya
    Rosell, Rafael
    Pavlakis, Nick
    Links, Matthew
    Gebski, Val
    Gralla, Richard J.
    Yang, James Chih-Hsin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (17) : 1958 - U142
123